The debate over whether insurance should cover GLP-1 agonists like Ozempic, Wegovy, and Mounjaro is being framed as a moral struggle between greedy insurers and a public in the throes of an obesity epidemic. This framing is a lie. It is a manufactured crisis designed to funnel trillions of dollars from employer-sponsored health plans and taxpayer-funded programs directly into the balance sheets of three or four pharmaceutical giants.
The "lazy consensus" argues that we should treat obesity like a chronic disease, covering the $1,000-a-month cost of these drugs because they save money on heart attacks and diabetes later. This logic is a fiscal hallucination. The math does not work. The biology does not work. The long-term health outcomes are a giant question mark that we are currently gambling our entire healthcare economy on.
The Mathematical Impossibility of "Savings"
Let’s burn the most common argument to the ground first: the idea that covering these drugs is "cost-effective."
To be "cost-effective" in the world of actuarial science, a drug must prevent enough expensive medical events—strokes, bypass surgeries, dialysis—to offset its own price tag. GLP-1s fail this test spectacularly. In the United States, roughly 42% of the adult population is obese. If every eligible person were prescribed a GLP-1 at current list prices, the annual cost would exceed $400 billion.
That is more than Americans spend on all other retail prescription drugs combined.
For an insurer to break even, that $400 billion spend would have to prevent $400 billion in immediate healthcare costs. But obesity-related complications develop over decades, not months. Most employees stay with an insurance provider for less than five years. Why would Company A spend $60,000 over five years to prevent a heart attack that might happen when the patient is 70 and covered by Medicare?
They wouldn't. They don't. And forcing them to do so via government mandates doesn't create "savings"—it creates a massive, immediate hike in premiums for everyone else. You aren't "saving" the system money; you are redistributing wealth from healthy workers to Novo Nordisk and Eli Lilly.
The Myth of the "Chronic Disease" Cure
We are told obesity is a chronic disease, implying it requires lifelong pharmacological intervention. If we accept this premise, we must also accept the consequences: these are not "weight loss" drugs; they are "weight maintenance" drugs.
Clinical trials, including the STEP trials for semaglutide, show that when patients stop taking the medication, they regain two-thirds of the weight within a year. This isn't a round of antibiotics. This is a subscription model for your metabolism.
[Image of GLP-1 receptor agonist mechanism of action]
By pushing for universal insurance coverage, we are effectively advocating for a permanent tax on the human body. We are committing to paying $12,000 a year, per person, forever, to suppress an appetite that is being hyper-stimulated by a broken industrial food system. We are medicating a symptom while the environment that causes the disease remains profitable and untouched.
Sarcopenia: The Hidden Health Crisis
The "weight loss at any cost" crowd ignores what is actually being lost. On a GLP-1, you aren't just losing adipose tissue. You are losing lean muscle mass at an alarming rate—sometimes up to 40% of the total weight lost.
In the medical world, we call this "sarcopenic obesity." You end up "thin," but with the metabolic profile of a frail 80-year-old. Muscle is the primary engine of glucose disposal and the protector of bone density. By forcing insurance companies to fund rapid, drug-induced weight loss without aggressive resistance training and protein intake protocols—which these drugs often make difficult due to nausea and "food noise" suppression—we are creating a generation of people who are lighter but physically weaker and potentially more prone to falls, fractures, and metabolic rebound.
I have seen corporate wellness programs jump at the chance to include these drugs, thinking they will lower their "risk score." They are in for a shock. When their workforce hits age 55 with 30% less muscle mass than their predecessors, the disability claims for musculoskeletal issues will dwarf the savings from fewer gallbladder surgeries.
The False Equivalence to Statin Therapy
Proponents love to compare GLP-1s to statins. "We cover Lipitor, so why not Wegovy?" they ask.
This is a category error. Statins are pennies per dose. They have 40 years of safety data. More importantly, they don't require the entire healthcare infrastructure to be rebuilt to accommodate them. GLP-1s require constant monitoring, titration, and management of significant gastrointestinal side effects.
Imagine a scenario where 100 million Americans are on a drug that causes 10% of users to experience severe vomiting or gastroparesis. The burden on primary care physicians and ERs would be catastrophic. We are talking about a systemic shock that our already-fragile healthcare delivery system cannot absorb.
The Brutal Reality of "Price Discovery"
Why are these drugs $1,300 in the U.S. and $100 in Germany? Because the U.S. insurance system is designed to hide the true cost from the consumer.
When you demand "insurance coverage," you are demanding that the price remain high. Insurance companies and Pharmacy Benefit Managers (PBMs) love high list prices because they negotiate "rebates" based on those prices. The higher the price, the bigger the rebate, and the more profit the middlemen scrape off the top.
If we want these drugs to be accessible, we should stop asking insurance to cover them. We should demand they be priced for the mass market. If these drugs were $50 a month—which they could be, given the manufacturing costs—we wouldn't be having a debate about "coverage." People would just buy them. By demanding insurance coverage, you are actually the biggest ally of Big Pharma’s pricing department. You are ensuring the price stays high enough to require an intermediary.
The "People Also Ask" Trap
People often ask: "Isn't it cheaper to treat obesity than its complications?"
The answer is: Not at these prices. If you treat 100 people for obesity to prevent 2 people from getting diabetes, you have spent $6 million (at $1,000/month for 5 years) to save perhaps $200,000 in diabetes management. The ROI is negative. It’s a bad business deal.
Another common question: "Is it a matter of equity?"
Actually, universal coverage might be the least equitable move possible. As premiums rise to cover the massive cost of GLP-1s, the working poor—who are already struggling to afford healthcare—will be priced out of their plans entirely. You are taxing the person who can't afford a premium hike to pay for the "bio-hacking" of the upper-middle class.
The Real Solution: Decouple Health from Pharma
Stop looking to your insurer to solve your metabolic health. They are a bill-paying entity, not a wellness coach.
If you want to disrupt the obesity epidemic, don't ask for a pill covered by a bloated insurance plan. Demand a food system that doesn't poison you. Demand urban planning that allows for movement. If you must use the drugs, treat them as a "kickstart" rather than a lifetime crutch.
But for the love of the economy, stop asking for insurance to pick up the tab. Because when insurance "covers" it, you’re still paying for it—through lower wages, higher premiums, and a bankrupt national treasury.
You’re not fighting the system. You’re becoming its most profitable customer.
